AI assistant
Sending…
Kymera Therapeutics, Inc. — Director's Dealing 2021
Feb 25, 2021
31145_dirs_2021-02-24_56716320-9477-4d8c-9b83-1fd47ebd6587.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kymera Therapeutics, Inc. (KYMR)
CIK: 0001815442
Period of Report: 2021-02-22
Reporting Person: Gollob Jared (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-22 | Common Stock | S | 9104 | $52.6285 | Disposed | 75507 | Direct |
| 2021-02-23 | Common Stock | S | 19285 | $49.6528 | Disposed | 56222 | Direct |
| 2021-02-24 | Common Stock | S | 8675 | $50.9131 | Disposed | 47547 | Direct |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
More from Kymera Therapeutics, Inc.
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Mar 27
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 25
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4